Navigation Links
YM BioSciences appoints Dr. Nick Glover as President and Chief Operating Officer
Date:6/3/2010

MISSISSAUGA, ON, June 3 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), today announced the appointment of Dr. Nick Glover to the newly created position of President and Chief Operating Officer. Dr. Glover will provide broad leadership to the Company and have primary responsibility for its operations and infrastructure, in particular the development and commercialization of YM's pipeline.

"After the successful merger of Cytopia into YM and with the further support of our investors, we have built YM into a vibrant company with a portfolio of promising late-stage products matched by a strong balance sheet. Given the potential of this outstanding platform, the Board and I believe that this is a critical opportunity in YM's development to similarly strengthen the leadership of the Company," said David Allan, Chairman and CEO of YM BioSciences. "Nick's operational experience, skill-set and leadership style are an ideal fit with YM BioSciences. His experience running a public company, in particular one that conducted international clinical trials in similar cancer indications as nimotuzumab, is a perfect complement for this role. In addition to this expertise, his background in small molecule drug design and his doctoral degree in chemistry are an excellent match for our JAK inhibitor and VDA programs."

Dr. Glover was formerly the President and Chief Executive Officer at Viventia Biotech Inc., a biopharmaceutical company involved in the discovery and development of monoclonal antibody-based technologies for the treatment of cancer. While at Viventia, Dr. Glover led the strategic development of a novel monoclonal antibody discovery platform, advancing three clinical products including a Phase III antibody for the treatment of advanced head and neck
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
2. YM BioSciences raises US$3.2 million in support of JAK 1/2 program
3. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
4. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
5. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
6. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
7. YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting
8. YM BioSciences third quarter 2010 operational and financial results
9. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
10. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
11. YM BioSciences announces controlled equity offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 zFlo Motion , a US ... an exciting product from a new partner. STT-Systems ... the past 15 years, with offerings in the optical-motion capture, ... IMU system (inertial measurement unit), iSen, is opening eyes around ...
(Date:1/22/2015)... 2015 Controlled Substance Compliance Services (CSCS), ... companies check the legal requirements around using controlled substances ... , As their international operations expand and become ... solutions built as a result of the first phase ...
(Date:1/22/2015)... January 22, 2015 Diagenode, Inc., ... as the Bioruptor® and complete solutions for epigenetics ... chromatin immunoprecipitation, alleviating the need for manual processing. ... needed for ChIP of histones or transcription factors ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
Breaking Biology Technology:3D Motion Capture Just Got Easy 2Global Compliance Service for Controlled Substances to Expand to China 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4
... Pharmasset, Inc. (Nasdaq: VRUS ) announced today ... the FDA on the final design for a phase 2b ... slated to initiate in the first quarter of this year."We ... 2b trial," stated Michelle Berrey, MD, MPH, Pharmasset,s Chief Medical ...
... Special Meeting to Enable Stockholders to Determine Fate ... Inc. Offers Avigen Stockholders Extraordinary Risk/Reward OpportunitySAN FRANCISCO, ... with its affiliates ("BVF") today announced that it ... Avigen, Inc. ("Avigen") (Nasdaq: AVGN ) ...
... VANCOUVER, Jan. 9 /PRNewswire/ - Sirius Genomics, a ... has signed a collaborative agreement with the United ... focuses on the continued development of Sirius, pharmacogenomic ... (sold by Eli Lilly and Company under the ...
Cached Biology Technology:Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 2Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 3Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 4Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 5Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees 2Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees 3Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees 4Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees 5Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group 2
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button Synaptics ... http://photos.prnewswire.com/prnh/20130307/600769 ... iPhone 5S, Samsung introduces for the first time a ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally transforming ... than at international borders. Over the past decade, ePassports, ... travelers to self process through border control via eGates ... number of airports, seaports, and land borders across the ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... University of California, Santa Cruz, who pioneered the use of ... compiled one of the largest datasets available for any marine ... in unprecedented detail. A new study published May ... the annual migrations of adult female elephant seals, with data ...
... Inc. (NASDAQ: AWRE ), a global provider ... it is providing biometrics software and services for three ... team-based project wins in Europe, the Middle East, and ... provide system integrators with a full suite of COTS ...
... drug made from the saliva of the Gila monster ... Researchers at the Sahlgrenska Academy, University of Gothenburg, have ... their cravings for both food and chocolate. An ... are offered a pharmaceutical preparation called Exenatide, which helps ...
Cached Biology News:Elephant seal tracking reveals hidden lives of deep-diving animals 2Elephant seal tracking reveals hidden lives of deep-diving animals 3Aware Provides Biometrics Software and Services for Three Large-Scale Border Management Systems 2Aware Provides Biometrics Software and Services for Three Large-Scale Border Management Systems 3Drugs from lizard saliva reduces the cravings for food 2
geminin, DNA replication inhibitor...
Normal human serum, single donor...
One-step, microplate or cuvet, colorimetric, linear detection range 0.1 mg/dL to 100 mg/dL. Procedure: 20 min....
... Certified USDA Research Registered OLAW Assured AAALAC ... AALAS Certified Technicians Documentation ... Upon Request Focus CRP is ... your custom immunology service needs. We ...
Biology Products: